Transfusion Medicine/Hemostasis Clinical Trials Network-Data Coordinating Center

输血医学/止血临床试验网络-数据协调中心

基本信息

项目摘要

DESCRIPTION (provided by applicant) The overall goal of the Transfusion Medicine/Hemostasis Clinical Trials Network (TMH CTN) is to conduct multi-center clinical studies to evaluate treatments and management strategies for children and adults with hemostatic disorders and methods of transfusion support for a variety of patient populations. The New England Research Institutes, Inc. (NERI) will continue to support the TMH CTN as Data Coordinating Center (DCC). The DCC has the following aims: 1) to collaborate in the selection, design, conduct, analysis and reporting of clinical studies and trials; 2) to develop a mechanism for patient recruitment and retention from out-of-network centers; 3) to manage protocol fund disbursement to both core and non-core sites; 4) to develop and maintain a data management system for each network study; 5) to institute quality control procedures including training site study personnel and conducting site visits; 6) to identify central laboratories and central review panels, and develop a system for tracking lab specimens and results; 7) to compile, edit, analyze and report study data; and 8) to coordinate the activities and meetings of the Steering Committee, and provide materials for PRC and DSMB members. During its first four years, the network has begun 3 clinical trials, and has 4 other studies nearing the final stages of development. These ongoing and planned studies include adjudication of specific clinical eligibility criteria and endpoints, a central ultrasound reading facility, and several central laboratories. The Transfusion Medicine/Hemostasis Clinical Trials Network will have an impact on the standard of care by investigating the efficacy, safety, and healthcare policy implications of treatment strategies in transfusion medicine and hematology. Conducting multicenter clinical trials within this network will provide sufficient subjects to evaluate important hypotheses regarding therapy and management in the respective patient populations. Study findings will be disseminated to the medical and scientific communities. The Transfusion Medicine/Hemostasis Clinical Trials Network plans and carries out studies in two areas of medicine. Transfusion Medicine studies investigate which patients need to be treated by giving transfusions, and which types and doses of transfusions to give. Hemostasis studies investigate disorders that put people at increased risk for serious bleeding or blood clots, and how to treat these disorders. DATA COORDINATING CENTER CRITIQUES
描述(由申请人提供) 输血医学/止血临床试验网络(TMH CTN)的总体目标是进行多中心临床研究,以评估患有止血疾病的儿童和成人的治疗和管理策略以及各种患者人群的输血支持方法。新英格兰研究所NERI将继续支持TMH CTN作为数据协调中心(DCC)。DCC有以下目标:1)在临床研究和试验的选择、设计、实施、分析和报告方面进行合作; 2)开发一种从网络外中心招募和保留患者的机制; 3)管理向核心和非核心研究中心支付的方案资金; 4)开发和维护每项网络研究的数据管理系统; 5)建立质量控制程序,包括培训研究中心人员和进行研究中心访问; 6)确定中心实验室和中心审查小组,并建立跟踪实验室样本和结果的系统; 7)汇编、编辑、分析和报告研究数据; 8)协调指导委员会的活动和会议,并为PRC和DSMB成员提供材料。在最初的四年里,该网络已经开始了3项临床试验,另有4项研究接近开发的最后阶段。这些正在进行和计划进行的研究包括特定临床合格性标准和终点的裁定、中心超声阅读机构和几个中心实验室。输血医学/止血临床试验网络将通过调查输血医学和血液学治疗策略的有效性、安全性和医疗保健政策影响来影响护理标准。在该网络内进行多中心临床试验将提供足够的受试者,以评价有关各自患者人群治疗和管理的重要假设。研究结果将分发给医学和科学界。输血医学/止血临床试验网络计划并开展两个医学领域的研究。输血医学研究调查哪些患者需要输血治疗,以及输血的类型和剂量。止血研究调查使人们严重出血或血凝块风险增加的疾病,以及如何治疗这些疾病。 数据协调中心评论

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SUSAN FERA ASSMANN其他文献

SUSAN FERA ASSMANN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SUSAN FERA ASSMANN', 18)}}的其他基金

BEST-CLI Trial-DCC
BEST-CLI 试用-DCC
  • 批准号:
    8371073
  • 财政年份:
    2013
  • 资助金额:
    $ 575.95万
  • 项目类别:
PITCH HF (DCC)
音高 HF (DCC)
  • 批准号:
    8294128
  • 财政年份:
    2012
  • 资助金额:
    $ 575.95万
  • 项目类别:
PITCH HF (DCC)
音高 HF (DCC)
  • 批准号:
    8459908
  • 财政年份:
    2012
  • 资助金额:
    $ 575.95万
  • 项目类别:
Transfusion Medicine/Hemostasis Research Network: DCC
输血医学/止血研究网络:DCC
  • 批准号:
    7122530
  • 财政年份:
    2002
  • 资助金额:
    $ 575.95万
  • 项目类别:
Transfusion Medicine/Hemostasis Research Network: DCC
输血医学/止血研究网络:DCC
  • 批准号:
    6665070
  • 财政年份:
    2002
  • 资助金额:
    $ 575.95万
  • 项目类别:
Transfusion Medicine/Hemostasis Clinical Trials Network-Data Coordinating Center
输血医学/止血临床试验网络-数据协调中心
  • 批准号:
    7690695
  • 财政年份:
    2002
  • 资助金额:
    $ 575.95万
  • 项目类别:
Transfusion Medicine/Hemostasis Research Network: DCC
输血医学/止血研究网络:DCC
  • 批准号:
    6935986
  • 财政年份:
    2002
  • 资助金额:
    $ 575.95万
  • 项目类别:
Transfusion Medicine/Hemostasis Research Network: DCC
输血医学/止血研究网络:DCC
  • 批准号:
    6786754
  • 财政年份:
    2002
  • 资助金额:
    $ 575.95万
  • 项目类别:
Transfusion Medicine/Hemostasis Clinical Trials Network-Data Coordinating Center
输血医学/止血临床试验网络-数据协调中心
  • 批准号:
    8139165
  • 财政年份:
    2002
  • 资助金额:
    $ 575.95万
  • 项目类别:
Transfusion Medicine/Hemostasis Clinical Trials Network-Data Coordinating Center
输血医学/止血临床试验网络-数据协调中心
  • 批准号:
    7932163
  • 财政年份:
    2002
  • 资助金额:
    $ 575.95万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 575.95万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 575.95万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 575.95万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 575.95万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 575.95万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 575.95万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 575.95万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 575.95万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 575.95万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 575.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了